| Literature DB >> 24658687 |
Giovanni Sorrentino1, Naomi Ruggeri1, Valeria Specchia2, Michelangelo Cordenonsi3, Miguel Mano4, Sirio Dupont3, Andrea Manfrin3, Eleonora Ingallina1, Roberta Sommaggio5, Silvano Piazza6, Antonio Rosato5, Stefano Piccolo3, Giannino Del Sal1.
Abstract
The YAP and TAZ mediators of the Hippo pathway (hereafter called YAP/TAZ) promote tissue proliferation and organ growth. However, how their biological properties intersect with cellular metabolism remains unexplained. Here, we show that YAP/TAZ activity is controlled by the SREBP/mevalonate pathway. Inhibition of the rate-limiting enzyme of this pathway (HMG-CoA reductase) by statins opposes YAP/TAZ nuclear localization and transcriptional responses. Mechanistically, the geranylgeranyl pyrophosphate produced by the mevalonate cascade is required for activation of Rho GTPases that, in turn, activate YAP/TAZ by inhibiting their phosphorylation and promoting their nuclear accumulation. The mevalonate-YAP/TAZ axis is required for proliferation and self-renewal of breast cancer cells. In Drosophila melanogaster, inhibition of mevalonate biosynthesis and geranylgeranylation blunts the eye overgrowth induced by Yorkie, the YAP/TAZ orthologue. In tumour cells, YAP/TAZ activation is promoted by increased levels of mevalonic acid produced by SREBP transcriptional activity, which is induced by its oncogenic cofactor mutant p53. These findings reveal an additional layer of YAP/TAZ regulation by metabolic cues.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24658687 DOI: 10.1038/ncb2936
Source DB: PubMed Journal: Nat Cell Biol ISSN: 1465-7392 Impact factor: 28.824